Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) concluded the trading on Wednesday, Sep 16, with a fall of -0.62% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $3.2 and 5Y monthly beta was reading 1.83 with its price kept floating in the range of $2.9100 and $3.2100 on the day. Company’s P/E ratio for the trailing 12 months is 0. Considering stock’s 52-week price range provides that MRNS hit a high price of $4.07 and saw its price falling to a low level of $1.01 during that period. Over a period of past 1-month, stock came adding 65.63% in its value.
With its current market valuation of $378.9 Million, Marinus Pharmaceuticals, Inc. is set to declare its quarterly results on August 06, 2020. MRNS Stock’s Forward Dividend of 0 and its yield of 0 are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Analysts are in estimates of -$0.15 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.71 for 2020 with estimates of that growing to -$0.55 in next year. These estimates are suggesting current year growth of -0.28% for EPS and -0.23% growth next year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with 4 upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review MRNS stock’s current outlook then short term indicators are assigning it an average of Hold, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 100% Buy for it.
According to ratings assigned by 9 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; none of them are recommending Marinus Pharmaceuticals, Inc. (MRNS) as a Hold, while 8 are in view that stock is a Buy. Recommendation by 1 analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Buy and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the MRNS stock which is currently positioned at 0. It further provides that stock’s current price level is 59.52% away from its 20-day simple moving average and is 64.22% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 80.76 while volatility remained at 14.13% over the past week which changes to 10.25% when measuring it over the past month. Beta is valued at 1.83, while measure of average true range or ATR is currently at 0.29. In predicting price targets of as low as $5 and as high as $9, analysts are in agreement on assigning the stock over the next 12 months average price target of $7.25. Stock’s current price level is 57.23% above from estimated low price target while it is 183.02% below the estimated high; and even if the MRNS’s share succeeded to reach the median price of $7.5, then the outlook of +135.85% could come to the excitement of the investors.
In comparing Marinus Pharmaceuticals, Inc. (MRNS)’s stock with other industry players reveals that stock’s latest price change of -0.62% and that of +82.76% over the past 12 months is in better position with that of Zoetis Inc Cl A (ZTS) which saw its stock price fell by -0.63% in the recent trading and went through an increase of 31.72% in past 12-month trading. Industry’s another major player Takeda Pharmaceutical Co. Ltd (TAK) has jumped 1.68% up in latest trading session, but over the past year has faced a rise of 7.64%, while Catalent Inc (CTLT) is also down -0.62% however its price remained floating in the green at 82.76% over the same period. Marinus Pharmaceuticals, Inc. has a P/E ratio of 0 against that of Zoetis Inc Cl A’s 47.69 while Takeda Pharmaceutical Co. Ltd is showing 23.08 for the same. On the other hand, the S&P 500 Index was down -0.46% in the early deals while the Dow Jones Industrial was dealing higher at 0.13%.
Having a second look at Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) provides that stock’s average daily trading volume for 3 months was 4.58 Million, while it dropped to 30.46 Million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock currently stood at 122.19 Million.
Data compiled by Thomson Reuters highlights that percentage of outstanding shares held by the insiders is 0.63% while it is 70.29% for the institutional holders. The figures also indicate that as of August 30, 2020, number of stock’s short shares was 14800000 which implies a short ratio of 7.34. This shows up a 12.11% of Short Interest in company’s outstanding shares on the day. In August the standing of shares short improved as it was 10.67 Million in the previous month. Addition of +47.22% by stock’s current price to its year-to-date value in today’s trading is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.